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Summary
Background: Advancement in diagnosis and treatment of various
cancer entities led to an increasing incidence of brain metastases in
the last decades. Surgical excision of single and multiple brain
metastases is one of the central treatment options beside radio-
therapy, radiosurgery and chemotherapy. To evaluate the benefit of
surgery with/without whole-brain radiation therapy (WBRT) in single
brain metastases and the influence of image guidance for brain
metastases resection, 104 patients were retrospectively evaluated
for post-operative outcome. Patients and Methods: Between
January 1994 and December 1999 150 patients were surgically
treated for brain metastases at the Department of Neurosurgery at
the Technical University of Dresden. Outcome could be evaluated in
104 patients with respect to special treatment strategies and survival
time (69 patients with single and 35 patients with multiple lesions).
Results: Most metastases originated from primary lung and breast
tumours. Karnofsky performance score improved on average by 10
after surgery. The extent of the extracerebral tumour burden was the
main influence on survival time. Patients’ age below 70 years was
combined with prolonged survival time (median survival time, MST:
4.5 months vs. 7 months). Patients with solitary cerebral metastasis
had a MST of 16 months, whereas patients with singular lesions has
a MST of 7 and 4 months, depending on the extent of the extracere-
bral tumour growth. Additional post-operative WBRT with 30 Gy was
combined with an increase in MST in patients with single brain
metastasis (surgery + WBRT: MST 13 months; surgery only: MST 8
months). In addition, the rate of recurrent cerebral tumour growth
was distinctly higher in the non-WBRT group. Neuronavigation did
not significantly improve post-operative survival time. In 80% of
patients extracerebral tumour growth limited patients’ survival.
Conclusion: Surgery is an initial treatment option in patients with
single and multiple brain metastases especially with large tumours
(> 3 cm). Post-operative WBRT seems to prolong survival time in
patients with single brain metastasis by decreasing local and distant
tumour recurrence. Neuronavigational devices permit a targeted
approach. Multiple processes can be extirpated in one session with-
out prolonging the hospitalisation time for the patient. However,
neuronavigational devices cannot assure complete tumour resection.
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Zusammenfassung
Hintergrund: Fortschritte in der Diagnostik und Therapie von Krebs-
erkrankungen haben in den letzten Jahrzehnten zu einer steigenden
Inzidenz von Hirnmetastasen geführt. Die chirurgische Entfernung
singulärer und multipler Hirnmetastasen stellt neben Strahlenthera-
pie, Radiochirurgie und Chemotherapie eine zentrale Therapieoption
dar. Um die Wertigkeit der chirurgischen Behandlung von singulären
Hirnmetastasen mit/ohne Ganzhirnbestrahlung (WBRT) und den
Einfluss der Neuronavigation zu untersuchen, wurden 104 Patienten
retrospektiv bezüglich ihres postoperativen «Outcomes» untersucht.
Patienten und Methoden: Zwischen Januar 1994 und Dezember 1999
wurden 150 Patienten mit Hirnmetastasen in der Klinik für Neuro-
chirurgie der Technischen Universität Dresden operiert. Das «Out-
come» von 104 Patienten konnte bezüglich der verschiedenen
Behandlungsstrategien und Überlebenszeit ausgewertet werden (69
Patienten mit singulären und 35 Patienten mit multiplen Läsionen).
Ergebnisse: Die meisten Metastasen stammen von Lungen- und
Mammakarzinomen. Nach operativer Behandlung verbesserte sich
der Karnofsky-Index um durchschnittlich 10. Das Ausmaß der extra-
zerebralen Tumormasse stellte die Haupteinflussgröße für die Über-
lebenszeit dar. Ein Lebensalter unter 70 Jahren war mit einer verlän-
gerten Überlebenszeit verbunden (mittlere Überlebenszeit, MÜZ: 
4,5 Monate vs. 7 Monate). Patienten mit solitären Metastasen hatten
eine MÜZ von 16 Monaten, während Patienten mit singulären Lä-
sionen, abhängig vom Ausmaß des extrazerebralen Tumorwachs-
tums, eine MÜZ von 7 bzw. 4 Monaten aufweisen. Eine zusätzliche
postoperative WBRT mit 30 Gy zeigte eine Verbesserung der MÜZ
bei Patienten mit singulären Hirnmetastasen (OP + WBRT: MÜZ
13 Monate; OP allein: MÜZ 8 Monate). Gleichzeitig war die Rate der
zerebralen Tumorrezidive in der Nicht-WBRT Gruppe deutlich höher.
Die postoperative Überlebenszeit wurde durch Verwendung der
Neuronavigation nicht signifikant verbessert. In 80% der Patienten
limitierte das extrazerebrale Tumorwachstum die Überlebenszeit.
Fazit: Bei Patienten mit singulären und multiplen Metastasen stellt
die initiale chirurgische Tumorentfernung eine Therapiealternative
insbesondere bei großen Tumoren (> 3 cm) dar. Eine postoperative
WBRT scheint die ÜLZ der Patienten mit singulären Hirnmetastasen
durch Begrenzung des Auftretens von Rezidivtumoren zu verlängern.
Die Neuronavigation erlaubt eine gezielte Zugangsplanung. Multiple
Prozesse können einzeitig operiert werden, ohne dass die postope-
rative stationäre Verweildauer verlängert wird. Hingegen wird eine
radikale Tumorentfernung durch Verwendung der Neuronavigation
nicht gewährleistet.
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Introduction
Cerebral metastases comprise more than 30% of brain tumours
[1–3]. They occur in 30–40% of all cancer patients. Most brain
metastases originate from primary lung cancer (35%) and
breast cancer (21%).At the time of diagnosis more than 50% of
the patients already have multiple lesions. In recent years brain
metastases have been diagnosed more frequently because of
the increasing life-span of people, the advancement in diag-
nostic tools and the optimised treatment of cancer patients
which gives brain metastases more time to develop [4].
Generally, the occurrence of brain metastases is associated
with the final stage of the metastasising process. At this stage
life expectancy is very limited. Therefore the goal in treating
patients is to eliminate the life-threatening brain lesion while
maintaining or optimising quality of life. To date, there are
several therapy modalities available to treat these patients.
They range from surgical procedures, over radiosurgery, radio-
therapy and chemotherapy to supportive care alone [5–8].
Selection of the appropriate treatment strategy for an indivi-
dual patient can be difficult. Several prognostic factors have
been stressed to mainly influence the survival time of the
patients: control of the primary tumour, extent of extra-
cerebral metastases, time interval between diagnosis of the
primary tumour and the development of the cerebral lesions,
number of cerebral lesions, Karnofsky performance scale score
and age [9–14].
After operative treatment the median survival time of patients
with a single lesion averages about 1 year, and in patients with
multiple lesions it is about 6–12 months [8, 12, 14–16]. Surgical
treatment of brain metastases is usually followed by post-oper-
ative whole-brain radiation therapy (WBRT) with 30–40 Gy.
Surgery plus WBRT is superior to WBRT alone [17, 18]. How-
ever, it is still controversial as to whether WBRT is necessary
after complete extirpation of a single brain metastasis. In 1998,
a first prospective randomised multicentre trial was published
evaluating surgery only vs. surgery plus WBRT in patients with
single brain metastasis [19]. The results demonstrate that pa-
tients treated with surgery alone have significantly more local
and distant recurrences than those receiving surgery plus
WBRT. The overall survival time and the length of time pa-
tients stayed functionally independent showed, however, no
significant differences.
In the last few decades neurosurgical procedures have been
optimised by technical advances, e.g. intra-operative ultra-
sound, neuronavigation, intra-operative magnetic resonance
imaging and brain mapping. Operative extirpation of small,
deep-seated or multiple lesions has become possible without
increasing the risk of worsening patients’ quality of life. The
exact planning of the operative approach by computer simula-
tion offers a safe and reproducible method. Multiple lesions
can be operated on in one session, avoiding a prolongation of
hospitalisation time [20–22].
The aim of this retrospective study was to evaluate different
treatment strategies and the survival time of patients treated
during the last few years for a single or multiple brain metas-
tases at our institution. The study explored two questions:
i) How did postoperative WBRT in patients with a single
brain metastasis influence outcome and survival time?
ii) Do intra-operative technical advances, e.g. neuronaviga-
tional devices, lead to a prolonged survival time of patients
with single and multiple cerebral metastases?
Patients and Methods
From January 1994 until December 1999, 150 patients with brain metas-
tases were operated on at the Department of Neurosurgery, Technical
University of Dresden. The patients were divided into two groups:
Group 1: Patients with a single brain metastasis.
Group 2: Patients with multiple brain metastases.
For the retrospective study a questionnaire was designed. Patients’ data
were evaluated with respect to different treatment strategies and survival
time. The following factors were taken into consideration: origin of the
primary tumour, time interval between the primary tumour and the
development of cerebral lesions, extent of extra-cerebral tumour burden,
number of cerebral lesions, surgery with neuronavigational devices, adju-
vant radiation therapy and age. Quality of life was assessed by using the
Karnofsky performance score. Extra-cerebral tumour progression was
defined in three stages:
i) Lack of extra-cerebral disease
ii) Stable disease
iii) Progressive disease.
Lack of extra-cerebral disease was defined as no extra-cerebral tumour
growth, either at the primary site or in other organs. Stable disease in-
cluded patients with tumour growth at the primary site, but without extra-
cerebral metastases. Progressive disease included patients with tumour
growth at the primary site and metastases to other extra-cerebral organs.
Statistical analysis was performed using the SPSS software program.
Kaplan-Meier survival analysis was applied to obtain survival rates. Multi-
variate Cox regression and discriminant analysis were calculated to iden-
tify additional factors.
Surgical Procedure for Patients with Single and Multiple Brain Metastases
The cerebral lesions were diagnosed by magnetic resonance imaging
(MRI). Cortical lesions were approached by using anatomical landmarks
to plan the osteoplastic trephination. For extirpation of multiple or deep-
seated cerebral metastases the operation was planned pre-operatively
using computers with neuronavigational devices. After application of
fiducials on the patient’s scalp an MRI volume scan in a thickness of 1 to 
2 mm was performed. The two-dimensional data were transferred to
computer three-dimensional imaging. The calculated data made it possible
to visualise the tumours through the scalp, skull and brain surface (fig. 1).
Computer imaging enabled us to plan the surgical approach by avoiding
additional iatrogenic neurological deficits. Multiple lesions could be extir-
pated in one session by performing small craniotomies at different sites of
the skull.
Results
Out of 150 patients, 104 responded to the questionnaire. 69 pa-
tients had suffered from a single brain metastasis and 35 from
multiple lesions. In single brain metastasis, 35 patients were
male, 34 patients female. In multiple lesions, 20 patients were
male, 15 patients female.
Distribution of the Primary Tumour Site and Location of the
Cerebral Metastasis
The distribution of the primary tumours is shown in figure 2. In
patients with a single brain metastasis the lung was the organ
of origin for 24%, the breast for 19%, unknown primaries for
13%, colon and kidney for 12% each and malignant melanoma
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for 10%. In multiple cerebral lesions (fig. 2) the organ distri-
bution again demonstrated a preference for the lung and
breast with 21% and 16% respectively followed by the pri-
mary colon, malignant melanoma and unknown primaries
with 13% each, the kidney with 6% and finally an equal dis-
tribution of 3% for the ovaries, cervix, bladder, thyroid, testis
and oesophagus.
Most cerebral metastases were located in the frontal lobe,
followed by the parietal, occipital, temporal lobe and the cere-
bellum in declining frequency (fig. 3).
Age and Karnofsky Performance Score
Median age was 61 years in patients with single brain metastasis
and 58 years in those with multiple cerebral metastases. Pa-
tients older than 70 years of age had a median survival time of
4.5 months and patients under 70 years of age 7 months.
The Karnofsky score averaged about 70 pre-operatively and 
80 post-operatively in patients with single lesions. In patients
with multiple tumours it averaged about 60 pre-operatively and
70 post-operatively. Four patients (2 with single and 2 with mul-
tiple lesions) suffered from post-operative complications: lung
emboli, wound infection and progressive pulmonary metas-
tases, post-operative haemorrhage and subdural empyema. The
Karnofsky score dropped about 40–60 points (table 1).The pre-
operative and post-operative Karnofsky scores of >70 and >80
respectively proved to be statistically significant with respect to
survival time (p = 0.023 and p = 0.0001 respectively) (fig. 4).
Cerebral Metastasis and Survival Time
The median survival time for patients with a single brain
metastasis was 10 months and for those with multiple brain
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Fig. 1. a Axial T1-weighted MRI after gadolinium showing two left frontal
cerebral metastases. On the right side of the figure the tumour borders
were marked. On the left side the tumour is visualised by a 3D surface
rendering process. b 3D reconstruction of the head surface of a patient
with multiple brain metastases. The tumour contours are visualised
through the scalp.
Fig. 2. Distribution of the primary tumour site of patients with single
(n = 69) and multiple brain metastases (n = 35).
metastases 6 months (p = 0.046) (fig. 5). However, 20% of the
patients with single lesions lived longer than 16 months, and
19% of the patients with multiple lesions survived more than
10 months. In patients with multiple lesions the number of
cerebral metastases did not prove to be a relevant factor for
survival time. In most of the tumours the time interval between
the primary tumour and the development of cerebral metasta-
sis was not found to be a significant factor for survival time.
Only in brain metastases of breast carcinoma the time interval
showed a statistically significant influence on survival time
(p = 0.020).
Progress of Extra-Cerebral Tumour Growth 
The progress of extra-cerebral tumour growth influenced the
median survival time. Patients with a single brain metastasis
but no extra-cerebral tumour growth showed a median sur-
vival time of 16 months, those with stable disease of 7 months
and those with active tumour progress of only 4 months
(p = 0.26) (fig. 6).
Fig. 4. a Kaplan-Meier survival curve of patients with brain metastases de-
pending on pre-operative Karnofsky score (Karnofsky score >70, median
survival time 12 months vs. Karnofsky score ≤ 70 , median survival time =
6 months) (p = 0.023) and b post-operative Karnofsky score (Karnofsy
score > 80, median survival time 14 months vs. Karnofsky score ≤ 80, median
survival time 5 months) (p = 0.0001).
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Fig. 3. Regional distribution of cerebral metastases in 69 patients with
single and 35 patients with multiple brain metastases.
Table 1. Pre- and post-operative Karnofsky performance score and post-
operative survival time of 4 patients with post-operative complications
Complications Preop. Postop. Survival
KPS KPS time, months
Lung emboli 60 20 0
Wound infection and progressive 
pulmonary metastases 80 20 2
Post-operative haemorrhage 60 40 0
Subdural empyema 80 40 1
Preop. KPS = Pre-operative Karnofsky performance score; Postop. KPS:
post-operative Karnofsky performance score.
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In all patients with multiple lesions extra-cerebral tumour
growth was apparent, involving two additional organs.
Neuronavigation 
Neuronavigation as an operative technique was evaluated with
respect to survival time in patients with single and multiple
lesions. Neuronavigation allows a targeted approach and was
applied in patients in whom a conventional operative approach
might be harmful. Median survival time was prolonged in
Karnofsky score > 70
Karnofsky score ≤ 70
Karnofsky score > 80
Karnofsky score ≤ 80
a
b
Surgical Resection and WBRT
28 patients with a single brain metastasis received surgery
alone and 31 surgery plus adjuvantWBRT.The selection to one
of both treatment groups was based on the intra-operative
extent of tumour removal and post-operative CT scan. Patients
with incomplete tumour removal were selected for adjuvant
WBRT and patients with complete tumour removal for
surgery only. In the group receiving surgery plus WBRT, the
median survival averaged about 13 months, whereas in the
surgical group median survival time was reduced to 8 months
(p = 0.15) (fig. 8a).
patients in whom neuronavigational devices were applied
(16 months vs. 10 months in patients with a single metastasis,
p = 0.76; 11 months vs. 5 months in those with multiple lesions,
p = 0.19) (fig. 7). However, the results were statistically not
significant.
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Multiple brain metastases
Single brain metastases
Fig. 5. Kaplan-Meier survival curve of patients with single (median sur-
vival time 10 months) and multiple brain metastases (median survival time
6 months) (p = 0.046).
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Stable disease
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Fig. 6. Kaplan-Meier survival curve of patients with cerebral metastases
with respect to extra-cerebral tumour growth (progressive disease, median
survival time 4 months vs. stable disease, median survival time 7 months vs.
no extra-cerebral disease, median survival time 16 months) (p = 0.26).
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Fig. 7. Kaplan-Meier survival curve of patients undergoing surgical resec-
tion for cerebral metastases with and without neuronavigational guidance.
a Patients with single lesions (with navigation,mean survival time16 months
vs. without navigation median survival time 10 months) (p = 0.76). b Pa-
tients with multiple lesions (with navigation, median survival time 11 months
vs. without navigation, median survival time 5 months) (p = 0.19).
In multiple cerebral lesions post-operative radiotherapy was
applied on a routine basis whenever possible.All patients were
treated with 30 Gy WBRT, receiving 1.5 Gy/day. In the treat-
ment group receiving surgery plus radiotherapy the median
survival time amounted to 8 months, and in 9 cases with
surgery alone survival time was 1 month (p = 0.03) (fig. 8b). In
all cases with multiple cerebral metastases, extra-cerebral
tumour burden was apparent, and metastatic seeding involved
at least two additional extra-cerebral organs.The overall medi-
an survival time of both groups, multiple and single metastases,
amounted to 8 months in the surgery plus WBRT group and 
6 months in the surgery alone group (p = 0.099) (fig. 8c).
Recurrence of Tumour Growth
In the group with post-operative radiation therapy, including
patients with a single metastasis as well as those with multiple
lesions, local recurrent tumour growth occurred in 13%, distant
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Fig. 8. Kaplan-Meier survival curve of patients with cerebral metastases
with respect to post-operative radiotherapy. a Patients with single lesions
(with radiotherapy, mean survival time, 13 months vs. without radiotherapy,
median survival time 8 months) (p = 0.15). b Patients with multiple lesions
(with radiotherapy, median survival time 8 months vs. without radio-
therapy, median survival time 1 months) (p = 0.03). c All patients with
cerebral metastases (with radiotherapy, median survival time 8 months vs.
without radiotherapy, median survival time 6 months) (p = 0.099).
a c
b
metastasis in 9% and local and distant metastases in 11% of the
patients. 67% of the patients had no recurrent cerebral seed-
ing. In patients not receiving post-operative radiotherapy, 22%
developed local re-growth, 11% distant metastases and 14%
both local re-growth and distant metastases. 53% of the pa-
tients did not develop recurrent cerebral tumour growth
(p = 0.24) (fig. 9). 44 patients underwent surgery after tumour
regrowth. Median interval to re-growth was 4.5 months. Me-
dian survival time after re-operation amounted to 6 months.
Chemotherapy was not applied on a routine basis, and pre-
operative radio- or chemotherapy had no influence on post-
operative survival (data not shown).
In 80% death was caused by the progression of extra-cerebral
tumour growth. Only in 20% were cerebral metastases respon-
sible for death.
Discussion
The prognosis of patients with cerebral metastases is poor.
Median survival time averages about 1 year, applying proven
treatment modalities, including surgery, radiotherapy and
chemotherapy. Several parameters have been identified as
relevant factors for prognosis: control of the primary tumour,
extent of extra-cerebral metastases, time interval between
diagnosis of the primary tumour and development of cerebral
lesions, number of cerebral lesions, Karnofsky performance
scale score and age [9–14].
tiple metastases. Patients older than 70 years of age had a
survival time of only 4.5 months compared to patients under 
70 years of age who survived 7 months. The major reason for
the diminished life expectancy was multimorbidity and there-
fore a reduction in the compensatory capacity of the patients.
The decision to conduct operative treatment should depend on
the biological age of the patient. Active treatment strategies
are also justified in older patients who are still young biologi-
cally and who do not suffer from other diseases.
Patients with solitary lesions have the best prognosis of all pa-
tients suffering from brain metastases. In these patients the
primary tumour should be under control and extra-cerebral
metastases are absent. According to recent publications, the
median survival time ranges between 12 and 18 months [13–17,
23]. It is known that in cases of solitary brain lesions surgical
removal of the cerebral lesion can even lead to a long-term
survival of more than 10 years [24, 25]. In our series patients
with solitary cerebral lesions had a median survival time of
16 months. Some of them, however, were long-term survivors
who lived more than 4 years. In all patients whole-body tumour
staging was performed. No extra-cerebral tumour growth was
apparent. One of the obvious problems in defining patients
with a solitary metastasis is the unknown number of those who
have undetected extra-cerebral tumour growth. Extra-cerebral
metastases influence survival time significantly. In our study we
distinguished between patients without systemic disease, with
stable extra-cerebral tumour burden and with progressive
disease. Patients without systemic disease had the best progno-
sis (a median survival time of 16 months). Patients with stable
disease showed a median survival time of 7 months, whereas
progressive extra-cerebral tumour disease reduced the median
survival time to 4 months. Smalley et al. [15] reported on 
229 patients with a solitary or singular brain metastasis. Pa-
tients without systemic disease and total extirpation of the
metastatic lesion had a median survival time of 1.3 years,
whereas patients with systemic disease and subtotal removal of
the brain tumour survived only 5.3 months. Besides the
amount of extra-cerebral tumour burden, the extent of tumour
resection is another important prognostic factor. It has been
confirmed by several publications that incomplete tumour re-
section reduces survival time significantly [15, 26]. In order to
determine whether a brain metastasis has been removed com-
pletely or not, it should be mandatory to evaluate all patients
post-operatively by an MRI scan with contrast media within
the first 48 h. Albert et al. [27] demonstrated that intra-paren-
chymal tumour residues leading to a disruption of the blood-
brain barrier can be discovered post-operatively by early con-
trast-enhanced MRI. The investigation has to be performed
within the first 48 h after tumour removal. Contrast enhance-
ment at the tumour margins is suggestive of remaining tumour.
MRI scans performed at a later time may already present with
marginal enhancement at the resection cavity caused by the
beginning of the repair process. In our study 31 patients with a
single brain metastasis received post-operative WBRT, ap-
plying 30 Gy (median survival time 13 months), whereas 28 pa-
tients did not (median survival time 8 months). The selection
criteria for adjuvant WBRT was the extent of intra-operative
tumour removal. Patients in whom tumour removal was
incomplete received adjuvant radiotherapy post-operatively.
Surgery is the treatment of choice for a single brain metastasis.
Lesions larger than 3 cm in diameter should be removed surgi-
cally whenever accessible as they lead to increased intra-
cranial pressure. The decision to operate depends on the clini-
cal status of the patient. Patients in good clinical condition with
a Karnofsky performance scale score of 70 have been shown to
profit from surgical intervention [11–13]. In our series the
median Karnofsky score averaged about 70 in patients with a
single brain metastasis and 60 in patients with multiple cere-
bral lesions. In both groups the Karnofsky score improved by
about 10 points post-operatively. A pre-operative Karnofsky
score >70 and a post-operative score > 80 was demonstrated to
be a significant factor for prolongation of the survival time. In
4 patients post-operative complications occurred, reducing the
Karnofsky score by about 40–60 points. In these cases the pa-
tients’ survival time was mainly influenced by the complication.
As age is known to be a relevant factor for outcome, this was
also evaluated in our group. Patients under 60 years of age
have a better prognosis than those over 60 years [14]. The
median age of our patients amounted to 61 years for patients
with single brain metastasis and 58 years for those with mul-
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Fig. 9. a Frequency and location of recurrent tumour growth in patients
with cerebral metastases after tumour resection and post-operative radio-
therapy and b tumour resection only (p = 0.24).
a
b
However, the extent of tumour removal was not confirmed by
early post-operative MRI scan. As mentioned above, there is
still no agreement as to whether patients with a single brain
metastasis should be irradiated post-operatively or not. Consi-
dering the fact that brain metastases are usually well circum-
scribed and grow less invasive than primary brain tumours,
complete tumour removal may be sufficient to avoid local re-
growth. Statistical analysis of our patients revealed that pa-
tients with post-operative WBRT developed fewer local or
distant cerebral metastases than those without WBRT even
though the radiation group was supposed to have incomplete
surgical tumour removal. Our groups were too small to reach
statistical significance. Evidence that post-operative WBRT
reduces cerebral recurrent tumour growth has been published
by others [28]. The randomised prospective trial by Patchell et
al. [19] comparing surgery vs. surgery plus radiotherapy con-
firms the relevance of post-operative radiotherapy. In this
study all patients were evaluated post-operatively by MRI
scan. Complete tumour removal was assured.Adjuvant WBRT
prevented recurrent tumour growth with statistical significan-
ce although the overall survival time could not be prolonged.
One has to keep in mind not only that tumour cells might be
left at the operation site causing local re-growth but also that,
considering the process of metastasising, small tumour cell
clumbs not visible by MRI have already seeded and start di-
viding. These initial tumours might be destroyed by WBRT.
Correlation of survival time to organ distribution of the pri-
mary tumours demonstrates a significant relationship between
these two parameters only in case of brain metastases from
primary breast tumour. A significant parameter in survival
time after diagnosis of a brain metastasis is the time interval
between manifestation of the primary tumour and onset of the
first symptoms of the cerebral lesion [11]. Especially in breast
carcinoma, the time interval between the primary tumour and
brain metastasis can take years. In our series, patients with
breast carcinoma and in some cases with malignant melanoma
also demonstrated the longest time interval, ranging between 
4 and 13 years. In these cases the time interval between the
primary tumour and the development of the cerebral metas-
tasis correlated with prolonged survival time. However, only
for breast carcinoma a statistical significance was found. In an
analysis of recently published studies evaluating survival time
of patients with surgically treated brain metastases from dif-
ferent primaries (colon carcinoma [10], non-small cell lung
cancer [14], renal carcinoma [29], breast carcinoma [23], malig-
nant melanoma [13]), no significant difference in patient’s out-
come was obvious. Only breast carcinoma patients with
tumours that were hormone receptor-positive had significantly
longer survival times than those with tumours that were hor-
mone receptor-negative (21.9 months vs. 12.5 months) [30].
There is an indication for re-operation if the time interval be-
tween the first cerebral metastasis and recurrent tumour growth
is longer than 4 months and the patient has a Karnofsky 
score of more than 60 [31, 32]. Patients can profit from surgical
management in cases of recurrent tumour growth. In the publi-
cation by Bindal et al. [32] median survival time ranged about
11.5 months. In our series 44 patients had tumour re-growth.
Median interval to re-growth was 4.5 months. Median survival
time after re-operation amounted to 6 months.
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Surgical treatment of multiple brain metastases is still a matter
of debate. The detection of a certain number of brain metasta-
ses by MRI does not exclude others. Tumours at a very initial
state might be undetected, even in T2 or flare-weighted MRI
sequences. The indication for active treatment strategies
depends on the Karnofsky score, the extent of extra-cerebral
tumour growth and the number of cerebral lesions. Multiple
cerebral lesions can be treated by WBRT, by surgery or by
radiosurgery [5–8, 18, 33]. Also supportive care only might be
justified, especially in cases of reduced clinical conditions, e.g.
Karnofsky score < 50.Reasons for surgical extirpation are large
tumours with a diameter of more than 3 cm, causing elevated
intra-cranial pressure and the need for histological confirma-
tion. In unknown primaries histological confirmation of the
cerebral process has to be demanded.
Today, two treatment modalities are available to approach
multiple brain metastases in a targeted manner: radiosurgery
by linear accelerator or gamma knife and surgery [8, 12, 14, 20,
21, 34–37]. Up to three cerebral lesions can be removed either
by surgery or radiosurgery. For radiosurgery the diameter 
of the tumours should not exceed 3 cm [34, 35]. Technical 
advances in neurosurgery make it possible to operate on mul-
tiple cerebral lesions in one session. Neuronavigational de-
vices allow for a targeted operative approach. Multiple and
deep-seated lesions can be extirpated without causing additio-
nal neurological deficits. With the aid of neuronavigation mul-
tiple brain metastases were removed in our series. 35 patients
were operated on, and the number of extirpated lesions 
ranged between 2 and 4. The tumours were removed in one
session. Most frequently patients suffered from primary lung,
primary breast cancer, malignant melanoma or unknown pri-
maries. When surgery was applied, post-operative complica-
tions only occurred in 2 patients causing the Karnofsky score
to drop. No additional morbidity was caused in any of the
other patients. Patients were sent home 8 days after the ope-
ration. Hospitalisation time was no longer than for patients
with a single brain metastasis, and the median survival time of
our patients amounted to 8 months. Post-operative WBRT
was applied on a routine basis. When WBRT could not be
performed, patients died within 1–3 months. Comparing the
survival time of patients operated on with neuronavigation
and those without, there was no statistically significant pro-
longation of survival time. The selection criteria we used for
neuronavigation partially explains the result. Neuronavigation
was applied if the tumour was deep-seated or close to function-
ally important areas of the brain, and the surgeon was trying
to avoid further deterioration as a result of the operative
procedure. If the tumour could be reached without any prob-
lem, no neuronavigation was performed. The other point that
must be considered is the limitation of neuronavigational
devices. Neuronavigation is a safe tool for approaching cere-
bral lesions and avoiding additional neurological deficits, but
it is not a tool for assuring complete extirpation of an intra-
parenchymal process. The problem involved relates to brain
shift. Since during the operation the data available have been
gathered pre-operatively, intra-operative brain shift caused by
cerebrospinal fluid (CSF) loss, volume reduction by extirpa-
tion of the tumour or retraction of brain regions by spatulas
cannot be calculated by the computer in real time. The only
Conclusion
Surgery is one of the proven treatment modalities for patients
with brain metastases.Especially large tumours (> 3 cm) should
be removed by surgical intervention.
Two main questions were addressed in our investigation:
i) The indication for post-operative adjuvant WBRT after
extirpation of a single brain metastasis.
ii) The value of neuronavigational devices in extirpation of
multiple brain lesions.
Our results have demonstrated that post-operative WBRT
subsequent to extirpation of a single brain metastasis may
prolong the survival time of the patient. Local and distant
tumour recurrence can be influenced, delayed or hindered.
However, if statistical significance is to be found, our group
must be enlarged.
Surgery is possible for single and multiple lesions. Also, small
or deep-seated tumours can be approached by an operation,
since neuronavigational devices permit a targeted approach
and avoid additional iatrogenic deficits. Multiple processes can
be extirpated in one session without prolonging the hospitali-
sation time for the patient. However, neuronavigational de-
vices cannot assure complete tumour resection. Therefore, no
effect on the prolongation of survival time can be expected.
MRI is the only adequate method of confirming complete
tumour resection, but one still has to bear in mind the biologi-
cal process of metastasising which involves the whole body and
will always limit the success of regional treatment strategies.
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tool that can confirm complete extirpation of a tumour intra-
operatively is intra-operative MRI [38].
After surgery or radiosurgery, the survival times of patients
with multiple brain metastases are comparable and range be-
tween 6 and 12 months. Recent publications have reported that
patients with more than two lesions have a significantly worse
prognosis than those with fewer than two lesions [35, 39]. In
our series of patients with multiple lesions the number of
cerebral metastases did not prove to be a significant factor for
survival time.
Our investigation showed that 80% of the patients died be-
cause of extra-cerebral tumour progress, whereas only 20%
died of cerebral metastases. The results of recent retrospective
studies and our own confirm that surgical management of
single and multiple cerebral metastases is appropriate to relieve
neurological symptoms and prolong the survival time of pa-
tients. However, as the course of the malignant cancer involves
the whole body, the success of local therapeutic strategies is
limited.
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